The Overlapping Spectrum of Ulcerative and Granulomatous Colitis: A Roentgenographic-Pathologic Study

Margulis, Alexander R.; Goldberg, Henry I.; Lawson, Thomas L.; Montgomery, Carolyn K.; Rambo, Oscar N.; Noonan, Charles D.; Amberg, John R.

doi:10.2214/ajr.113.2.325

Cited by 62 publications

(7 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…PPs are a common finding in IBD[ 13 ]. They are found more often in UC than in CD, and some authors have reported a double prevalence in UC as compared with colonic CD[ 25 ]. The reported prevalence rates vary from 4% to 74%[ 26 , 27 ], but most of the data supporting these findings was obtained from older studies that considered only UC.…”

Section: Prevalence Of Pp In Ibdmentioning

confidence: 99%

Pseudopolyps in inflammatory bowel diseases: Have we learned enough?

Politis

Κατσάνος

Tsianos

et al. 2017

WJG

View full text Add to dashboard Cite

Pseudopolyps are a well described entity in the literature and even though the exact pathogenesis of their formation is not completely understood, they are considered non-neoplastic lesions originating from the mucosa after repeated periods of inflammation and ulceration associated with excessive healing processes. Their occurrence is less common in Crohn's disease than in ulcerative colitis, and their overall prevalence ranges from 4% to 74%; moreover, they are found more often in colon but have been detected in other parts of the gastrointestinal tract as well. When their size exceeds the arbitrary point of 1.5 cm, they are classified as giant pseudopolyps. Clinical evaluation should differentiate the pseudopolyps from other polypoid lesions, such as the dysplasia-associated mass or lesion, but this situation represents an ongoing clinical challenge. Pseudopolyps can provoke complications such as bleeding or obstruction, and their management includes medical therapy, endoscopy and surgery; however, no consensus exists about the optimal treatment approach. Patients with pseudopolyps are considered at intermediate risk for colorectal cancer and regular endoscopic monitoring is recommended. Through a review of the literature, we provide here a proposed classification of the characteristics of pseudopolyps.

show abstract

Section: Prevalence Of Pp In Ibdmentioning

confidence: 99%

Pseudopolyps in inflammatory bowel diseases: Have we learned enough?

Politis

Κατσάνος

Tsianos

et al. 2017

WJG

View full text Add to dashboard Cite

show abstract

“…The difficulties in diagnosis are due to overlapping Received for publication 20 October 1977 in the pathological features of Crohn's disease and ulcerative colitis, which may even be opposite ends of a spectrum of one disease (Lewin and Swales, 1966;Margulis et al, 1971). But few, apart from Lewin and Swales (1966) and Glotzer et al (1970), have studied the pathology of these indeterminate cases in any detail.…”

mentioning

confidence: 99%

Overlap in the spectrum of non-specific inflammatory bowel disease--'colitis indeterminate'.

Ab¹

1978

J Clin Pathol

385

162

View full text Add to dashboard Cite

SUMMARY It is stated that 10-20O,' of cases of non-specific inflammatory bowel disease cannot be classified. Thirty such cases, designated colitis indeterminate at the time of colectomy, were identified from the pathology files of St. Mark's Hospital. The histopathological features of the surgical specimens and any available biopsy specimens were studied. In nearly all the cases urgent surgery had been required and the features of incipient or established fulminating disease were present.

show abstract

“…Collar button signs and longitudinal ulcers are observed in both CD and ulcerative colitis. 16 – 18 In the present case, an absent hematochezia and a positive noncaseating epithelioid granuloma led to a diagnosis of CD.…”

Section: Discussionmentioning

confidence: 58%

Crohn’s Disease Successfully Treated With Infliximab in a Patient Receiving Hemodialysis

Chiba

Tsuda²,

Tsuji³

et al. 2014

Medicine

View full text Add to dashboard Cite

There is limited information in the use of antitumor necrosis factor α, infliximab, in patients on hemodialysis. In Crohn’s disease (CD), only 3 cases are reported.A 76-year-old man on hemodialysis for renal failure caused by immunoglobulin A nephropathy developed diarrhea and abdominal pains. A marked edema was observed in the pretibia and ankle. An increase of C-reactive protein (CRP) and erythrocyte sedimentation rate, hypoalbuminemia, hypocholesterolemia, and moderate anemia was found. Ultrasonography and computed tomography (CT) found wall thickness in the left colon. Sigmoidoscopy revealed multiple ulcers in the sigmoid colon and noncaseating epithelioid granuloma was found in the biopsy specimen. Barium enema study exhibited collar button signs and longitudinal ulcers in the left colon.A severe form of CD was diagnosed. Metronidazole seemed to decrease CRP but was ineffective in ameliorating diarrhea. Infliximab rather than steroid hormone was chosen for the treatment. Standard induction therapy with infliximab was initiated. Symptoms rapidly improved then disappeared. CD activity index decreased from 747 to a remission level of 134 after 2 infusions of infliximab. Scheduled maintenance infliximab therapy was administered after the induction therapy. Ultrasonography and CT showed a disappearance of the wall thickness of the colon. Adverse reactions were not observed.Infliximab was effective and safe in a patient with CD on hemodialysis. Our case has added additional literature in accordance with previous reports supporting infliximab as effective and safe in patients on hemodialysis.

show abstract

The Overlapping Spectrum of Ulcerative and Granulomatous Colitis: A Roentgenographic-Pathologic Study

Cited by 62 publications

References 2 publications

Pseudopolyps in inflammatory bowel diseases: Have we learned enough?

Pseudopolyps in inflammatory bowel diseases: Have we learned enough?

Overlap in the spectrum of non-specific inflammatory bowel disease--'colitis indeterminate'.

Crohn’s Disease Successfully Treated With Infliximab in a Patient Receiving Hemodialysis

Contact Info

Product

Resources

About